Effect of ADM-assisted breast reconstruction on reducing the need for long-term (five year) revisional surgery compared to a submuscular technique
Association of Breast Surgery ePoster Library. Wilson R. 05/15/17; 166254; P092
Ms. Rebecca Wilson
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Rate & Comment (0)
Introduction
Core studies reported a five-year revision rate of 35-40% in implant-based reconstruction. There is little evidence to demonstrate the impact ADMs have on revision rates. Our aim was to compare the five-year revision rates between Strattice™-assisted reconstruction and a submuscular technique.
Methods
Retrospective case note, implant database and theatre log review of consecutive implant-based reconstructions performed from January 2009 -November 2011 with a minimum of five-years follow-up.
Results
117 patients underwent immediate implant-based reconstruction. 88 Strattice™-assisted (62 patients) and 49 submuscular (42 patients) reconstructions were included. Median follow-up was 5.7 years in the Strattice™-assisted group and 6.1 years in the submuscular. There was no significant difference in preoperative risk factors between groups.
The five-year revision rate, per patient, is 52% in both the Strattice™-assisted and submuscular group (p=0.9). In total, 45 (51%) Strattice™ reconstructions required revisional surgery compared to 26 (53%) submuscular (p=0.8).
There was no difference in the median time to first revisional surgery of 18 months (Strattice) versus 20 months (submuscular)(p=0.4).
Revision rates in those having prior or adjuvant radiotherapy are 53% in the Strattice™-assisted group (n=8) and 100% in the submuscular (n=5) (p=0.1).
There was a significant reduction in the need for revisional surgery for capsular contracture in the Strattice group (Strattice n=7, submuscular n=15, p=0.02).
Conclusions
Revision rates at five-years are equivalent between the Strattice™-assisted and submuscular reconstructions. Strattice™ may have particular benefit in preventing revisional surgery in those receiving chest wall radiotherapy and in reducing capsular contracture.
Core studies reported a five-year revision rate of 35-40% in implant-based reconstruction. There is little evidence to demonstrate the impact ADMs have on revision rates. Our aim was to compare the five-year revision rates between Strattice™-assisted reconstruction and a submuscular technique.
Methods
Retrospective case note, implant database and theatre log review of consecutive implant-based reconstructions performed from January 2009 -November 2011 with a minimum of five-years follow-up.
Results
117 patients underwent immediate implant-based reconstruction. 88 Strattice™-assisted (62 patients) and 49 submuscular (42 patients) reconstructions were included. Median follow-up was 5.7 years in the Strattice™-assisted group and 6.1 years in the submuscular. There was no significant difference in preoperative risk factors between groups.
The five-year revision rate, per patient, is 52% in both the Strattice™-assisted and submuscular group (p=0.9). In total, 45 (51%) Strattice™ reconstructions required revisional surgery compared to 26 (53%) submuscular (p=0.8).
There was no difference in the median time to first revisional surgery of 18 months (Strattice) versus 20 months (submuscular)(p=0.4).
Revision rates in those having prior or adjuvant radiotherapy are 53% in the Strattice™-assisted group (n=8) and 100% in the submuscular (n=5) (p=0.1).
There was a significant reduction in the need for revisional surgery for capsular contracture in the Strattice group (Strattice n=7, submuscular n=15, p=0.02).
Conclusions
Revision rates at five-years are equivalent between the Strattice™-assisted and submuscular reconstructions. Strattice™ may have particular benefit in preventing revisional surgery in those receiving chest wall radiotherapy and in reducing capsular contracture.
Introduction
Core studies reported a five-year revision rate of 35-40% in implant-based reconstruction. There is little evidence to demonstrate the impact ADMs have on revision rates. Our aim was to compare the five-year revision rates between Strattice™-assisted reconstruction and a submuscular technique.
Methods
Retrospective case note, implant database and theatre log review of consecutive implant-based reconstructions performed from January 2009 -November 2011 with a minimum of five-years follow-up.
Results
117 patients underwent immediate implant-based reconstruction. 88 Strattice™-assisted (62 patients) and 49 submuscular (42 patients) reconstructions were included. Median follow-up was 5.7 years in the Strattice™-assisted group and 6.1 years in the submuscular. There was no significant difference in preoperative risk factors between groups.
The five-year revision rate, per patient, is 52% in both the Strattice™-assisted and submuscular group (p=0.9). In total, 45 (51%) Strattice™ reconstructions required revisional surgery compared to 26 (53%) submuscular (p=0.8).
There was no difference in the median time to first revisional surgery of 18 months (Strattice) versus 20 months (submuscular)(p=0.4).
Revision rates in those having prior or adjuvant radiotherapy are 53% in the Strattice™-assisted group (n=8) and 100% in the submuscular (n=5) (p=0.1).
There was a significant reduction in the need for revisional surgery for capsular contracture in the Strattice group (Strattice n=7, submuscular n=15, p=0.02).
Conclusions
Revision rates at five-years are equivalent between the Strattice™-assisted and submuscular reconstructions. Strattice™ may have particular benefit in preventing revisional surgery in those receiving chest wall radiotherapy and in reducing capsular contracture.
Core studies reported a five-year revision rate of 35-40% in implant-based reconstruction. There is little evidence to demonstrate the impact ADMs have on revision rates. Our aim was to compare the five-year revision rates between Strattice™-assisted reconstruction and a submuscular technique.
Methods
Retrospective case note, implant database and theatre log review of consecutive implant-based reconstructions performed from January 2009 -November 2011 with a minimum of five-years follow-up.
Results
117 patients underwent immediate implant-based reconstruction. 88 Strattice™-assisted (62 patients) and 49 submuscular (42 patients) reconstructions were included. Median follow-up was 5.7 years in the Strattice™-assisted group and 6.1 years in the submuscular. There was no significant difference in preoperative risk factors between groups.
The five-year revision rate, per patient, is 52% in both the Strattice™-assisted and submuscular group (p=0.9). In total, 45 (51%) Strattice™ reconstructions required revisional surgery compared to 26 (53%) submuscular (p=0.8).
There was no difference in the median time to first revisional surgery of 18 months (Strattice) versus 20 months (submuscular)(p=0.4).
Revision rates in those having prior or adjuvant radiotherapy are 53% in the Strattice™-assisted group (n=8) and 100% in the submuscular (n=5) (p=0.1).
There was a significant reduction in the need for revisional surgery for capsular contracture in the Strattice group (Strattice n=7, submuscular n=15, p=0.02).
Conclusions
Revision rates at five-years are equivalent between the Strattice™-assisted and submuscular reconstructions. Strattice™ may have particular benefit in preventing revisional surgery in those receiving chest wall radiotherapy and in reducing capsular contracture.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}